Literature DB >> 9928752

Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function.

R Fogari1, A Zoppi, L Corradi, A Mugellini, P Lazzari, P Preti, P Lusardi.   

Abstract

The aim of this study was to compare the effects of ramipril and nitrendipine chronic treatment on urinary albumin excretion (UAE) in hypertensive patients with type II non-insulin-dependent diabetes mellitus (NIDDM) and impaired renal function. A 2-year, prospective, randomised study was conducted on 51 men with a diastolic blood pressure (DBP) > or =95 and < or =105 mm Hg, stable NIDDM, serum creatinine between 1.6 and 3.0 mg/dl and persistent UAE >300 and <2000 mg/24 h. After a 3-month preliminary observation period, during which patients began a low-protein, low-sodium diet, and a subsequent 4-week run-in period on placebo, patients were randomly treated with ramipril 5 mg or nitrendipine 20 mg for 2 years. Both drugs similarly reduced BP without affecting glucose homeostasis. In the ramipril group UAE significantly decreased after only 3 months of treatment, whereas in the nitrendipine group a significant although lesser reduction in UAE was observed only after 1 year. During the second year the UAE% change was not statistically different between the two treatments. Serum creatinine and creatinine clearance showed no significant change with both drugs. The progression of renal insufficiency as assessed by the rate of reduction of creatinine clearance over the 2 years of the study was similar in the ramipril and the nitrendipine groups. In conclusion both ramipril and nitrendipine were associated with a decrease in UAE although such a reduction was earlier and more marked with ramipril. The decline of renal function did not differ significantly between the two treatments.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9928752     DOI: 10.1038/sj.jhh.1000732

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  13 in total

Review 1.  Use of calcium antagonists in renal patients: therapeutic benefit or medical malpractice?

Authors:  Douglas A Nigbor; Julia B Lewis
Journal:  Curr Hypertens Rep       Date:  2003-10       Impact factor: 5.369

Review 2.  Dihydropyridine calcium channel blockers and renal disease.

Authors:  Nicolás R Robles; Francesco Fici; Guido Grassi
Journal:  Hypertens Res       Date:  2016-07-14       Impact factor: 3.872

3.  The case for combining angiotensin-converting enzyme inhibitors and calcium-channel blockers.

Authors:  A A Taylor; S Sunthornyothin
Journal:  Curr Hypertens Rep       Date:  1999-10       Impact factor: 5.369

Review 4.  Prevention and treatment of diabetic nephropathy in older patients.

Authors:  Eckart Jungmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 5.  Treatment of hypertension in diabetic patients with nephropathy.

Authors:  R Komers; S Anderson
Journal:  Curr Diab Rep       Date:  2001-12       Impact factor: 4.810

Review 6.  Ramipril: a review of its use in the prevention of cardiovascular outcomes.

Authors:  Gregory T Warner; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.

Authors:  George L Bakris; Matthew Weir
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Nov-Dec       Impact factor: 3.738

Review 8.  Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis.

Authors:  P Vejakama; A Thakkinstian; D Lertrattananon; A Ingsathit; C Ngarmukos; J Attia
Journal:  Diabetologia       Date:  2011-12-22       Impact factor: 10.122

Review 9.  Slowing the progression of adult chronic kidney disease: therapeutic advances.

Authors:  Maarten W Taal
Journal:  Drugs       Date:  2004       Impact factor: 11.431

Review 10.  Therapeutic approaches to slowing the progression of diabetic nephropathy - is less best?

Authors:  Eva Vivian; Chelsea Mannebach
Journal:  Drugs Context       Date:  2013-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.